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Opinion: Open Science
Open Science and Open Publishing: A New Paradigm for the
European Urology Family
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aDepartment of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France; bDepartment of Urology, The Netherlands Cancer Institute, Antoni van
Leeuwenhoek Hospital, Amsterdam, The Netherlands; cDepartment of Urology, Saint John Languedoc Hospital, Toulouse, France; dDepartment of Urology,
Universita Vita Salute San Raffaele, Milan, Italy; eAcademic Urology Unit, The University of Sheffield, Sheffield, UK
The way in which we consume information, entertainment,
and media is changing. Today everybody can access their
favorite song, book, or film online, and often for free. We
read about events through social media and react in real
time. We expect faster, shorter, and more accessible
content. This is true for our news feeds, our friendship
networks, and our medical journals. The European Urology
family has embraced these changes. We hope we have
adapted to deliver what our readers want and our patients
need. The journals have been online and digital since 2013,
our social media feeds have tens of thousands of followers,
we work 24/7 to engage our readers in our papers, and we
have embraced technology in every aspect of the editorial
process.
Medical publishing is under pressure to change, to reflect
the increasing digitalization of our world and to adapt to
new business models. Fully (Gold) open-access journals
have been around for at least a decade and were initially the
remit of separate publishing houses. Driven by readers,
funders of research, health care providers and patients, Gold
Open Access journals are becoming popular and estab-
lished, and so we address this with the launch of European
Urology Open Science. Open Science is placed to adopt,
embrace, and adapt new publishing models. As the name
indicates, the journal is 100% open access and publishes
high-quality science for all clinicians and individuals
treating or caring for urological patients. Urologists are
early adopters, whether for robotic surgery or social media
such as Twitter, and so urologists will embrace this new way
of publishing. We hope that Open Science will help to keep
our specialty at the forefront of modern publishing and to
keep up with trends observed in other media. Moreover, as
European Urology Open Science content is free to read for
everybody, we see opportunities for a completely new
audience for our articles. We think that Open Science will
broaden the attraction of urology as a specialty in general
and for the European Urology family beyond our current
readers.
At the same time, the open access philosophy assures
broad distribution of research and the highest possible rate
of true and complete reading of your work. This broad and
unrestricted access to the research published in European
Urology Open Science is made possible by shifting the costs
for publishing from the reader to the author, a similar
process to what has been observed in recent years for other
media publishing sources such as news, music, and films.
This approach is in line with Plan S, an initiative launched by
Science Europe in 2018 with wide support, including from
the European Commission. The plan requires scientists and
researchers who benefit from state-funded research orga-
nizations and institutions to publish their work in open
repositories or in journals that are available to all by
2021. We, and probably you as well, agree that access to the
most recent research should not be limited to those who can
afford it but to all who would like to read it. European
Urology Open Science represents an important step in
providing this broad availability.
Despite the unique nature of this edition, our ambition
for this journal is similar to that for the European Urology
family as a whole. We aim to use education and research to
improve the care of our patients. The European Urology Open
Science content will be high-quality urological research
coming from all fields of our specialty, including oncology,
functional urology, and basic research, delivering meaning-
ful, practice-changing evidence or clinical audits. Articles
published in Open Science will include original articles as
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well as video content, case series, trial protocols and up-to-
date reviews with continuing medical education credits.
The Open Science content will complement European
Urology, European Urology Focus, and European Urology
Oncology by offering broader appeal, open access publica-
tion, and slightly higher acceptance rates.
Our aim is to provide quick and high-quality peer review
and deliver the fastest way to get new research results
published and visible to readers. Articles will be published
online in four editions per year and will be made available as
soon as possible after acceptance of the proofs. Manuscripts
can be directly submitted to our journal via https://www.
editorialmanager.com/euros or may be offered this route
from our family journals. Additional and detailed informa-
tion about the journal can be found on our website at
https://www.eu-openscience.europeanurology.com/
You can follow the journal on Twitter at
@EurUrolOpen. We hope that you enjoy the journey and
thank you for your support.
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